DOD Biotech Public Company Limited (DOD.BK)

DOD Biotech Public Company Limited (DOD.BK) — VMCI valuation read

DOD Biotech Public Company Limited sits at VMCI 52/100, with the Consumer Defensive sector median at 50. That 2-point spread is the first thing to note on DOD.BK: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on DOD.BK are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on DOD.BK: DOD.BK trades at 26.0x earnings, 44% above the Consumer Defensive median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Consumer Defensive median (10.0%). The Risk read: net debt to EBITDA of 1.0x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

DOD.BK rose 3.3% over the trailing 7 days, with a -10.2% read on a 30-day basis.